Shanghai Ruising Gene Technology

Shanghai Ruising Gene Technology is a clinical-stage biotechnology company focused on the development of next-generation gene therapies for ophthalmic and neurological disorders. The company utilizes a proprietary adeno-associated virus (AAV) vector platform designed to enhance delivery efficiency and therapeutic durability. Its lead candidate, RSG-001, is currently being evaluated in clinical trials for the treatment of wet age-related macular degeneration (nAMD). Ruising Gene aims to replace frequent intravitreal injections with a single-dose gene therapy approach to improve patient compliance and outcomes. Based in Shanghai, the firm is backed by prominent venture capital investors including Northern Light Venture Capital and Legend Capital.